MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, has entered into a licensing agreement with Braingaze Ltd. (Braingaze) and launched its new business, Tris Digital Health, which will focus on the development and commercialization of digital diagnostic and therapeutic products for neurological health conditions..

新泽西州蒙茅斯交界处（商业新闻短讯）--Tris Pharma，Inc.（Tris），一家专注于注意力缺陷多动障碍（ADHD），疼痛，成瘾和神经系统疾病的商业阶段生物制药公司，已与Braingaze Ltd.（Braingaze）签订了许可协议，并推出了其新业务Tris Digital Health，该公司将专注于针对神经系统健康状况的数字诊断和治疗产品的开发和商业化。。

Tris has secured exclusive rights to develop and commercialize Braingaze’s digital ADHD diagnostic platform in the United States and Canada. Braingaze is a digital health company developing technology-driven diagnostic and treatment solutions for cognitive disorders.

Tris已获得在美国和加拿大开发Braingaze数字ADHD诊断平台并将其商业化的专有权。Braingaze是一家数字健康公司，开发技术驱动的认知障碍诊断和治疗解决方案。

There has been an unmet need in ADHD for more objective tools that can help healthcare providers diagnose this disorder. The launch of Tris Digital Health and licensing of Braingaze’s digital ADHD diagnostic platform underscore Tris’ commitment to deliver innovative health products that address pressing needs in neurological health through innovative new technologies..

多动症对更客观的工具的需求尚未得到满足，这些工具可以帮助医疗保健提供者诊断这种疾病。Tris数字健康的推出和Braingaze数字ADHD诊断平台的授权突显了Tris致力于通过创新的新技术提供创新的健康产品，以满足神经健康的迫切需求。。

“Patients, caregivers and physicians deserve better tools to support accurate ADHD diagnosis beyond the currently available options,” said Ketan Mehta, founder and CEO at Tris Pharma. “We have launched Tris Digital Health to deliver on our long-term commitment to advance meaningful and beneficial healthcare for physicians, ADHD patients and caregivers.

Tris Pharma创始人兼首席执行官科坦·梅塔（KetanMehta）表示：“除了目前可用的选择之外，患者、护理人员和医生应该拥有更好的工具来支持准确的多动症诊断。”。“我们推出了Tris数字健康，以履行我们的长期承诺，为医生、多动症患者和护理人员推进有意义和有益的医疗保健。

We are delighted to partner with Braingaze to launch this important endeavor and look forward to offering practitioners in the United States and Canada the opportunity to use and evaluate the benefits of this digital ADHD diagnostic platform.”.

我们很高兴与Braingaze合作，发起这项重要的努力，并期待着为美国和加拿大的从业者提供使用和评估这种数字ADHD诊断平台的好处的机会。”。

Braingaze’s first-in-class, digital biomarker-based ADHD diagnostic tool has been developed in Europe and carries the European CE Mark as a medical device. With input from the U.S. Food and Drug Administration (FDA), Tris Pharma will initiate clinical trials in the United States to further validate Braingaze’s technology as an objective ADHD diagnostic tool for clinical use in the United States and Canada..

Braingaze的第一款基于数字生物标志物的ADHD诊断工具已在欧洲开发，并带有欧洲CE标志作为医疗设备。根据美国食品和药物管理局（FDA）的意见，Tris Pharma将在美国启动临床试验，以进一步验证Braingaze的技术作为美国和加拿大临床使用的客观ADHD诊断工具。。

“We’ve received enthusiastic feedback from European physicians who tell us that our novel diagnostic test is an improvement over subjective tools they relied on until now,” said Laszlo Bax, CEO and co-founder of Braingaze. “We are thrilled to partner with Tris, another leader in the ADHD space who has an exceptional track record with four commercialized medications, to extend the reach of our ADHD diagnostic solutions to patients who might benefit from it in the United States and Canada.”.

Braingaze首席执行官兼联合创始人拉兹洛·巴克斯（LaszloBax）说：“我们收到了欧洲医生的热情反馈，他们告诉我们，我们的新型诊断测试比他们迄今为止所依赖的主观工具有所改进。”。“我们很高兴与多动症领域的另一位领导者Tris合作，Tris在四种商业化药物方面有着出色的业绩记录，将我们的多动症诊断解决方案的范围扩展到美国和加拿大可能受益于它的患者。”。

Braingaze’s AI-enhanced, digital biomarker-based technology is designed to support ADHD diagnosis in children and adults. It comprises a test involving a computerized game and patented eye-tracking technology to measure individuals’ attention. Based on these measures, the test provides physicians with ADHD probability and severity scores for individual patients..

Braingaze的人工智能增强数字生物标志物技术旨在支持儿童和成人的ADHD诊断。它包括一个涉及电脑游戏和专利眼动技术的测试，以测量个人的注意力。基于这些措施，该测试为医生提供了个体患者的ADHD概率和严重程度评分。。

“Tris analyzed multiple investigational ADHD digital diagnostic technologies and concluded that the Braingaze test substantially outperforms other tools designed to provide objective ADHD assessment and diagnosis,” said James Hackworth, Brand Division president at Tris Pharma. “We look forward to validating this technology in U.S.

Tris Pharma品牌部门总裁詹姆斯·哈克沃斯（JamesHackworth）表示：“Tris分析了多种研究性多动症数字诊断技术，并得出结论，Braingaze测试大大优于其他旨在提供客观多动症评估和诊断的工具。”。“我们期待着在美国验证这项技术。

patients, with the goal of providing patients, their caregivers and healthcare providers greater confidence in ADHD diagnoses to support improved outcomes.”.

患者，目的是为患者，其护理人员和医疗保健提供者提供对ADHD诊断的更大信心，以支持改善的结果。”。

About Tris Pharma

关于Tris Pharma

Tris Pharma is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain and neurological disorders, including addiction and diseases of the central nervous system. Tris is an established commercial organization with a robust portfolio of best-in-class ADHD products and a promising pipeline of differentiated, near-term drug candidates.

Tris Pharma是一家私营、创新驱动的生物制药公司，正在应用其药物开发能力和专有技术来改变ADHD、疼痛和神经系统疾病（包括成瘾和中枢神经系统疾病）的治疗方法。Tris是一家成熟的商业组织，拥有一流的ADHD产品的强大组合，以及有前途的差异化近期候选药物渠道。

More information is available at www.trispharma.com and on LinkedIn @TrisPharma..

更多信息请访问www.trispharma.com和LinkedIn@trispharma。。

About Tris Digital Health

关于Tris Digital Health

Tris Digital Health is a subsidiary of Tris Pharma focused on the development and commercialization of digital diagnostic and therapeutic products for mental health disorders. Tris Digital Health is focused on and committed to developing and commercializing easy-to-use digital products and services in the field of ADHD and other mental health conditions for the benefit of healthcare providers, payers, patients and their caregivers..

Tris Digital Health是Tris Pharma的子公司，专注于针对精神健康障碍的数字诊断和治疗产品的开发和商业化。Tris Digital Health专注于开发和商业化ADHD和其他心理健康领域易于使用的数字产品和服务，以造福于医疗保健提供者、付款人、患者及其护理人员。。

About Braingaze Ltd.

关于Braingaze Ltd。

Started in 2013, Braingaze utilizes patented proprietary technologies to innovate digital early detection and treatment in cognitive health. The company offers a patented, scientifically, and clinically validated biomarker-based decision support system for early and objective diagnosis of ADHD and is developing early detection solutions for Autism Spectrum Disorder and cognitive diseases such as Alzheimer's disease.

自2013年开始，Braingaze利用专利专有技术创新认知健康的数字早期检测和治疗。该公司为ADHD的早期和客观诊断提供了一个专利，科学和临床验证的基于生物标志物的决策支持系统，并正在开发自闭症谱系障碍和认知疾病（如阿尔茨海默病）的早期检测解决方案。

In addition, it is developing gamified digital treatment that has scientifically shown to substantially improve patients' cognitive health. Braingaze is working with leading clinics and hospitals in Europe and the United Kingdom on improving cognitive healthcare with its digital diagnostic and therapeutic tools.

此外，它正在开发游戏化数字治疗，科学证明可以大大改善患者的认知健康。Braingaze正在与欧洲和英国的领先诊所和医院合作，利用其数字诊断和治疗工具改善认知保健。

More information is available at www.braingaze.com and on LinkedIn @Braingaze..

更多信息请访问www.braingaze.com和LinkedIn@braingaze。。